Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With PrognosisKaren Dybkær, Hans Erik Johnsen, Martin Bøgsted et al.|Journal of Clinical Oncology|2015Cited by 125
High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphomaSara Correia Marques, Karen Dybkær, Martin Bøgsted et al.|Experimental Hematology|2016Cited by 68
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression modelsSteffen Falgreen, Martin Bøgsted, Karen Dybkær et al.|BMC Cancer|2015Cited by 65
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell linesLinn Reinholdt, Karen Dybkær, Maria Bach Laursen et al.|Biomarker Research|2016Cited by 31
High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patientsMaria Bach Laursen, Karen Dybkær, Linn Reinholdt et al.|Oncotarget|2019Cited by 28